 | Up a level |
Suenaga, Mitsukuni; Schirripa, Marta; Cao, Shu; Zhang, Wu; Yang, Dongyun; Cremolini, Chiara; Murgioni, Sabina; Lonardi, Sara; Ning, Yan; Okazaki, Satoshi; Berger, Martin D.; Miyamoto, Yuji; Barzi, Afsaneh; Loupakis, Fotios; Falcone, Alfredo; Lenz, Heinz-Josef (2020). Single Nucleotide Polymorphisms in MiRNA Binding Sites of Nucleotide Excision Repair-Related Genes Predict Clinical Benefit of Oxaliplatin in FOLFOXIRI Plus Bevacizumab: Analysis of the TRIBE Trial. Cancers, 12(7) MDPI AG 10.3390/cancers12071742
Miyamoto, Yuji; Schirripa, Marta; Suenaga, Mitsukuni; Cao, Shu; Zhang, Wu; Okazaki, Satoshi; Berger, Martin D.; Matsusaka, Satoshi; Yang, Dongyun; Ning, Yan; Baba, Hideo; Loupakis, Fotios; Lonardi, Sara; Pietrantonio, Filippo; Borelli, Beatrice; Cremolini, Chiara; Yamaguchi, Toshiharu; Lenz, Heinz-Josef (2020). A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer. PLoS ONE, 15(9), e0239439. Public Library of Science 10.1371/journal.pone.0239439
Suenaga, Mitsukuni; Cao, Shu; Zhang, Wu; Yang, Dongyun; Ning, Yan; Okazaki, Satoshi; Berger, Martin Dave; Miyamoto, Yuji; Schirripa, Marta; Soni, Shivani; Barzi, Afsaneh; Yamaguchi, Toshiharu; Lenz, Heinz-Josef (2019). Genetic variants in CCL5 and CCR5 genes and serum VEGF-A levels predict efficacy of bevacizumab in metastatic colorectal cancer patients. International journal of cancer, 144(10), pp. 2567-2577. Wiley-Blackwell 10.1002/ijc.31968
